Drug Profile


Alternative Names: CaCP 29; IFX-1

Latest Information Update: 25 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing Mabworks Biotech; InflaRx
  • Developer InflaRx
  • Class Anti-infectives; Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Complement C5a inhibitors; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hidradenitis suppurativa; Microscopic polyangiitis; Sepsis; Systemic inflammatory response syndrome; Wegener's granulomatosis
  • Phase I Inflammation

Most Recent Events

  • 15 Oct 2018 Phase-II clinical trials in Microscopic polyangiitis (Adjunctive treatment) in USA (IV) (NCT03712345)
  • 15 Oct 2018 Phase-II clinical trials in Wegener's granulomatosis (Adjunctive treatment) in USA (IV) (NCT03712345)
  • 28 Jun 2018 The US FDA approves IND application for IFX 1 in ANCA-associated vasculitis (AAV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top